News

Novo Nordisk slashes 9,000 jobs to slim down in fierce weight-loss drug battle

Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk’s breakup with Hims

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

1 Reason Every Investor Should Know About Novo Nordisk (NVO)

It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight ...

Novo Nordisk: Priced Like Best Days Are Over (Upgrade)

Novo Nordisk is deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% OP jump, and a rock-solid balance ...

Strong Danish economy can ride out Novo Nordisk downturn, finance minister says

Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, ...
Becker's Hospital Review6d

Wegovy gains new approval: 3 GLP-1 updates

Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA ...

Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal

Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.